Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Orphan drugs Stories

2014-04-07 08:30:00

Phase I Demonstrates Quizartinib Tolerability in Combination with Chemotherapy SAN DIEGO, April 7, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose...

2014-04-03 12:29:29

Poor Efficacy and Physicians' Desire for Personalized Therapeutics Will Provide Opportunity for Developers of New Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., April 3, 2014 /PRNewswire/ -- Decision Resources Group finds that azacitidine (Celgene's Vidaza, generics) will continue to be the patient share leader in treatment of myelodysplastic syndromes (MDS) in the United States and major European markets during the 2013-2023 study period. According to...

2014-03-31 08:29:52

Defitelio®? (defibrotide) Launch Announced During the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 2014 DUBLIN and VILLA GUARDIA, Italy, March 31, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Gentium S.p.A., a Jazz Pharmaceuticals company, today announced the commencement of the European commercial launch of Defitelio®(?) (defibrotide), the first licensed product for the treatment of severe hepatic veno-occlusive...

2014-03-27 08:35:29

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/48gc9x/therapeutic_class ) has announced the addition of the "Therapeutic Class Overview: Treating Refractory Hematological Malignancies" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable...

2014-03-26 08:23:02

DUBLIN, Mar. 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/pt8tl4/treating ) has announced the addition of the "Concise Analysis of New Methods for Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Targeting unmet needs in the treatment of cancer through innovative drug development strategies have...

2014-03-25 08:29:38

Pharmaceutical Executive Brings Additional Expertise in Oncology Drug Development and Commercialization SAN DIEGO, March 25, 2014 /PRNewswire/ -- Tocagen Inc. today announced that Jamey Skillings, M.D., has been named Senior Vice President and Chief Medical Officer. Dr. Skillings joins Tocagen from Pfizer, where she was most recently vice president of global medical affairs for oncology. Dr. Skillings' clinical leadership at prior pharmaceutical companies led to several oncology...

2014-03-04 12:26:52

Incentives for Pathway Compliance, Reduced Hospitalization are Changing Treatment, According to Findings from Decision Resources Group BURLINGTON, Mass., March 4, 2014 /PRNewswire/ -- Decision Resources Group finds that the increasing use of clinical pathway programs, accountable care organizations (ACOs) and bundled payments is changing the prescribing of oncology drugs in the treatment of colorectal cancer and renal cell carcinoma. As more payers and oncology practices adopt pathways,...

2014-02-28 08:25:51

SAN DIEGO, Feb. 28, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's investigational drug Pracinostat for the treatment of acute myeloid leukemia (AML). (Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO) "We are very pleased to receive this orphan drug...

2014-02-26 23:22:59

The global market for histone deacetylase inhibitors (HDIs) was valued at $223.2 million in 2012 and was estimated at $361.8 million for 2013. BCC Research expects the market to grow to $954.3 million by 2018, and register a five-year compound annual growth rate of 21.4% from 2013 to 2018. Wellesley, Mass. (PRWEB) February 26, 2014 According to a new technical market research report Histone Deacetylase Inhibitors: Emerging Markets, from BCC Research (http://www.bccresearch.com), the...

2014-02-11 08:32:20

-- Study Focused on Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Who are EphA3 Positive -- SOUTH SAN FRANCISCO, Calif., Feb. 11, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company has begun treating patients in the Phase 2 expansion portion of study KB004-01 evaluating KB004, the company's anti-EphA3 Humaneered(®) monoclonal antibody (mAb). The company is targeting enrollment of 30 patients for this portion of the Phase 2...